NRXP

Event Announcement: NRx Pharmaceuticals and HOPE Therapeutics will participate in an H.C. Wainwright fireside discussion on April 22, 2025, featuring CEO Jonathan Javitt discussing their biopharmaceutical developments.

Company Focus: NRx Pharmaceuticals is advancing treatments for central nervous system disorders, including NRX-101 for suicidal bipolar depression, while HOPE Therapeutics aims to establish a network of clinics offering innovative therapies for related mental health conditions.

Investment Announcement: HOPE Therapeutics has signed a term sheet for a $2.5 million investment to support the establishment of its network of clinics focused on treating suicidal depression and PTSD using innovative therapies like ketamine and TMS.

Company Vision: The investment aligns with HOPE's strategy to provide comprehensive interventional psychiatry treatments globally, addressing the significant unmet needs of patients suffering from severe mental health disorders.

Acquisition Announcement: HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical, which will enhance their interventional psychiatry services on Florida's west coast, focusing on treatments for severe depression and PTSD.

Leadership Appointment: Stephen Durand, founder of Dura Medical, will serve as Director of Clinic Operations for HOPE in Florida, aiming to treat over 10,000 individuals by 2026 and expand the network's reach.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Acquisition Announcement: HOPE Therapeutics, Inc. has signed a Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, which operates six interventional psychiatry clinics in Florida, aiming to enhance its network and revenue projections for 2025.

Services Offered: Neurospa provides a range of interventional psychiatry services, including Ketamine Infusion Therapy, Spravato®, and Transcranial Magnetic Stimulation (TMS), targeting patients with severe depression and related disorders in a patient-centered environment.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

New Drug Applications: NRx Pharmaceuticals has initiated filings for New Drug Applications (NDA) for NRX-100 (IV Ketamine) targeting Suicidal Depression and plans to file for NRX-101 for bipolar depression, with anticipated approval dates before December 31, 2025.

Expansion of HOPE Therapeutics: The company is acquiring multiple precision psychiatry centers to establish a national network for interventional psychiatry services, while also negotiating funding to support these expansions and aiming for profitability by the end of 2025.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Upcoming Financial Results Announcement: NRx Pharmaceuticals will release its fourth quarter and full year 2024 financial results on March 17, 2025, followed by a conference call at 8:30am ET to discuss the results and provide a corporate update.

Company Overview and Drug Development: NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including NRX-101 for suicidal bipolar depression and NRX-100 (IV ketamine) for suicidal depression, both of which have received FDA designations aimed at expediting their approval processes.

Upcoming Presentations: NRx Pharmaceuticals and HOPE Therapeutics will present updates at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025, with a live webcast available for viewers.

Company Focus: NRx Pharmaceuticals is developing treatments for central nervous system disorders, including NRX-101 for suicidal bipolar depression and chronic pain, while HOPE Therapeutics aims to establish interventional psychiatry clinics offering innovative therapies.

Upcoming Conferences: NRx Pharmaceuticals will present updates at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, and management will be available for one-on-one meetings in New York from February 10-12, 2025.

Company Developments: NRx is advancing its NMDA platform therapeutics, including NRX-101 for suicidal bipolar depression and chronic pain, and has initiated a New Drug Application filing for NRX-100 (IV ketamine) for suicidal depression, having received Fast Track Designation from the FDA.

Partnership Announcement: HOPE Therapeutics, Inc. has engaged BTIG as a financial advisor to assist in building a global network of interventional psychiatry clinics that will combine ketamine treatment with transcranial magnetic stimulation and digital therapeutics for severe depression and PTSD.

Funding Agreement: The company has secured $27 million in funding for clinic acquisitions and plans to leverage this investment alongside bank debt to establish its network of clinics aimed at addressing mental health issues.

HOPE Therapeutics' Plans: HOPE Therapeutics, Inc. is collaborating with BTIG to establish a global network of interventional psychiatry clinics that will utilize ketamine treatment, transcranial magnetic stimulation, and digital therapeutics for severe depression and PTSD, backed by a recent $27 million funding agreement.

BTIG's Role: BTIG will provide advisory services to HOPE, focusing on identifying clinic partners, evaluating strategic assets, and facilitating financing initiatives to support the company's expansion in mental health care.

Investment in HOPE Therapeutics: NRX Pharmaceuticals has secured a $27 million investment for its subsidiary, HOPE Therapeutics, aimed at expanding Interventional Psychiatry Clinics to treat severe depression and PTSD using innovative therapies.

Stock Performance: Following the announcement, NRX shares rose by 17.9%, trading at $3.36, as the company anticipates reaching a revenue threshold of $100 million and plans to raise an additional $400 million for further expansion.

Compliance with Nasdaq Requirements: NRx Pharmaceuticals has regained compliance with Nasdaq's minimum market value requirement, as confirmed by a notice received on January 17, 2025, indicating the matter is now closed.

Company Overview and Future Plans: NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including treatments for suicidal bipolar depression and chronic pain, with plans to file New Drug Applications for its investigational therapies.

Board Appointments: NRx Pharmaceuticals has appointed Michael Taylor and Anita Nunes to its Board of Directors, with Nunes also joining the Board of HOPE Therapeutics. Both bring extensive experience in finance, healthcare, and technology to support the company's growth.

Company Focus: NRx Pharmaceuticals is developing therapeutics for central nervous system disorders, including NRX-101 for suicidal bipolar depression and chronic pain, while HOPE Therapeutics aims to create a network of clinics offering innovative mental health treatments.

Ketamine Treatment and Expert Insight: Dr. David Feifel, founder of Kadima Neuropsychiatry Institute, was featured on CNN discussing the science and stigma surrounding ketamine treatment for depression, emphasizing the need for psychiatric supervision in controlled settings.

HOPE Therapeutics Acquisition: HOPE Therapeutics plans to acquire Kadima, with Dr. Feifel set to become Chief Medical Innovation Officer, aiming to enhance access to advanced psychiatric treatments like ketamine and transcranial magnetic stimulation for patients with severe depression.

Uplisting Application: NRx Pharmaceuticals has applied to uplist its securities to the NASDAQ Global Market, aiming to enhance liquidity for shareholders and meet institutional investment requirements, contingent on meeting specific listing criteria.

Company Overview: NRx Pharmaceuticals is focused on developing therapeutics for central nervous system disorders, including treatments for suicidal depression and PTSD, with ongoing applications for FDA approvals for their investigational drugs NRX-101 and NRX-100.

Investor Workshop Announcement: HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, held an investor workshop at Mar-A-Lago to discuss the expansion of its interventional psychiatry clinics aimed at treating suicidal depression and PTSD, with significant financing commitments and future clinic acquisition plans.

Future Plans and Developments: The company aims to establish a network of clinics utilizing advanced technologies and therapies, including ketamine treatments, while also preparing for an expanded meeting with investors later in January 2025.